Astec LifeSciences · NSE: ASTEC · BSE: 533138
Q4 FY19 results · Jan–Mar 2019
Astec LifeSciences reported revenue from operations of ₹133.76 crore and net profit of ₹12.73 crore for Q4 FY19 (Jan–Mar 2019), on a consolidated basis.
| Item | Q4 FY19 | Q4 FY18 | YoY | Q3 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 133.76 | — | — | 119.43 | +12.0% |
| Other income | 5.76 | — | — | 3.07 | +87.6% |
| Total income | 139.52 | — | — | 122.50 | +13.9% |
| Profit before tax | 20.22 | — | — | 15.33 | +31.9% |
| Net profit for the period | 12.73 | — | — | 9.98 | +27.5% |
| Attributable to shareholders of the company | 12.72 | — | — | 9.96 | +27.7% |
| EPS, basic (₹) | 6.50 | — | — | 5.10 | +27.5% |
| Net margin (%) | 9.5 | — | 8.4 |
| Item | Q4 FY19 | Q4 FY18 | YoY | Q3 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 133.76 | — | — | 119.43 | +12.0% |
| Other income | 5.74 | — | — | 3.03 | +89.2% |
| Total income | 139.50 | — | — | 122.46 | +13.9% |
| Profit before tax | 20.18 | — | — | 15.28 | +32.0% |
| Net profit for the period | 12.70 | — | — | 9.94 | +27.8% |
| EPS, basic (₹) | 6.50 | — | — | 5.09 | +27.7% |
| Net margin (%) | 9.5 | — | 8.3 |
Consolidated
- Filed with BSE
- 02 May 2019, 15:57 IST
- Board meeting
- 30 Apr 2019
- Period
- 01 Jan 2019 to 31 Mar 2019
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 02 May 2019, 15:57 IST
- Board meeting
- 30 Apr 2019
- Period
- 01 Jan 2019 to 31 Mar 2019
- Review status
- Audited
- Source
- XBRL filing on BSE